In Regard to Shuryak et al.

This commentary expresses our concerns regarding the article titled “Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks,” by Shuryak et al., published in the International Journal of Radiation Oncology, Biology, Physics.1 The authors aim to evaluate the benefit–risk balance o f low-dose radiation therapy (LDRT) for COVID-19. To do so, they estimated the lifetime risk of radiation-induced lung cancer and heart disease for patients with different background risks (e.g., sex, age, and the existence of other risk factors such as smoking and heart disease) by using what the a uthors call “state-of-the-art radiation risk models” for lung cancer and heart disease.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Risks of Low-Dose Pulmonary Radiotherapy for COVID-19 Source Type: research